1h Free Analyst Time
The obsessive-compulsive disorder drugs market is forecasted to grow by USD 348.54 mn during 2023-2028, accelerating at a CAGR of 5.93% during the forecast period. The report on the obsessive-compulsive disorder drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of OCD, launch of new molecules, and increasing awareness programs for OCD.
The obsessive-compulsive disorder drugs market is segmented as below:
By Product
- SSRI
- TSA
- Others
By Route Of Administration
- Oral
- Parentral
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the obsessive-compulsive disorder drugs market covers the following areas:
- Obsessive-compulsive disorder drugs market sizing
- Obsessive-compulsive disorder drugs market forecast
- Obsessive-compulsive disorder drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global obsessive-compulsive disorder drugs market: Alembic Pharmaceuticals Ltd., Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., BrainsWay Ltd., Dellwich Healthcare LLP, Eli Lilly and Co., Eridanus, flamingopharma.com, GlaxoSmithKline Plc, H Lundbeck AS, Jabs Biotech, Jazz Pharmaceuticals Plc, Kabir Lifesciences, Lepu Medical Technology Beijing Co. Ltd., Lifecare Neuro Products Ltd., Novartis AG, Omeros Corp., Pfizer Inc., SERVOMAX Ltd., Wellona Pharma, and Neurocon Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increased use of off-label therapies.'
According to the report, one of the major drivers for this market is the rising prevalence of OCD.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alembic Pharmaceuticals Ltd.
- Anant Pharmaceuticals Pvt. Ltd.
- Apotex Inc.
- BrainsWay Ltd.
- Dellwich Healthcare LLP
- Eli Lilly and Co.
- Eridanus
- flamingopharma.com
- GlaxoSmithKline Plc
- H Lundbeck AS
- Jabs Biotech
- Jazz Pharmaceuticals Plc
- Kabir Lifesciences
- Lepu Medical Technology Beijing Co. Ltd.
- Lifecare Neuro Products Ltd.
- Novartis AG
- Omeros Corp.
- Pfizer Inc.
- SERVOMAX Ltd.
- Wellona Pharma
- Neurocon Inc.